SEC Form 4 · accession 0001193125-26-335012
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric A Hughes
Officer — See "Remarks"
Period of report
Aug 3, 2026
Accepted (ET)
Aug 5, 2026 · 4:02 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000818686
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Aug 3, 2026 | M | 52,744 | — | A | 160,455 | D | |
| Ordinary SharesF1,F4,F5 | Aug 3, 2026 | S | 25,578 | $34.8757 | D | 134,877 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF2,F6,F1 | — | Aug 3, 2026 | M | 52,744 | D | — | — | Ordinary Shares | 52,744 | 0 | D |
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F3The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
- F4Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.66 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F6Restricted share units were granted on August 1, 2022, with 52,742 vested on each of August 1, 2023, August 1, 2024 and August 1, 2025, and 52,744 vested on August 1, 2026.
Remarks
Executive Vice President, Global R&D and Chief Medical Officer.